on GENSIGHT BIOLOGICS S.A. (EPA:SIGHT)
GenSight Biologics: Financial Report and Outlook
GenSight Biologics has reported its net cash position at the end of 2024, highlighting sufficient working capital through February 2025 thanks to capital increases completed at the end of the year. However, the company will still need to secure financing to cover its commitments beyond that date.
The company's cash position stands at €2.5 million, down from September 2024. The respective capital increases in November and December, totalling €4.3 million, nevertheless make it possible to consider continuing the Compassionate Access (CA) programme.
At the same time, the ANSM review process of the LUMEVOQ® dossier is underway, following the submission of the company's responses. Preparations for the RECOVER phase III clinical trial are also progressing.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all GENSIGHT BIOLOGICS S.A. news